Open AccessBenefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status
Author(s) -
L. Kristin Newby,
E. Magnus Ohman,
Robert H. Christenson,
David J. Moliterno,
Robert A. Harrington,
Harvey D. White,
Paul W. Armstrong,
Frans Van de Werf,
Matthias Pfisterer,
Vic Hasselblad,
Robert M. Califf,
Eric J. Topol
Publication year - 2001
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.103.24.2891
Subject(s) - medicine , myocardial infarction , acute coronary syndrome , troponin , placebo , odds ratio , cardiology , troponin t , clinical endpoint , randomized controlled trial , pathology , alternative medicine
Troponin T (TnT) is valuable for short- and long-term risk stratification of patients with acute coronary syndromes (ACS). It also may predict which ACS patients will benefit from glycoprotein (GP) IIb/IIIa blockade.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom